These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
538 related articles for article (PubMed ID: 27986708)
21. Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature. Albiol N; Novelli S; Mozos A; Pratcorona M; Martino R; Sierra J J Med Case Rep; 2021 Jun; 15(1):326. PubMed ID: 34172079 [TBL] [Abstract][Full Text] [Related]
22. The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells. Nechiporuk T; Kurtz SE; Nikolova O; Liu T; Jones CL; D'Alessandro A; Culp-Hill R; d'Almeida A; Joshi SK; Rosenberg M; Tognon CE; Danilov AV; Druker BJ; Chang BH; McWeeney SK; Tyner JW Cancer Discov; 2019 Jul; 9(7):910-925. PubMed ID: 31048320 [TBL] [Abstract][Full Text] [Related]
23. BET Inhibition Enhances the Antileukemic Activity of Low-dose Venetoclax in Acute Myeloid Leukemia. Ramsey HE; Greenwood D; Zhang S; Childress M; Arrate MP; Gorska AE; Fuller L; Zhao Y; Stengel K; Fischer MA; Stubbs MC; Liu PCC; Boyd K; Rathmell JC; Hiebert SW; Savona MR Clin Cancer Res; 2021 Jan; 27(2):598-607. PubMed ID: 33148670 [TBL] [Abstract][Full Text] [Related]
24. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. Blombery P; Anderson MA; Gong JN; Thijssen R; Birkinshaw RW; Thompson ER; Teh CE; Nguyen T; Xu Z; Flensburg C; Lew TE; Majewski IJ; Gray DHD; Westerman DA; Tam CS; Seymour JF; Czabotar PE; Huang DCS; Roberts AW Cancer Discov; 2019 Mar; 9(3):342-353. PubMed ID: 30514704 [TBL] [Abstract][Full Text] [Related]
25. Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression. Lochmann TL; Floros KV; Naseri M; Powell KM; Cook W; March RJ; Stein GT; Greninger P; Maves YK; Saunders LR; Dylla SJ; Costa C; Boikos SA; Leverson JD; Souers AJ; Krystal GW; Harada H; Benes CH; Faber AC Clin Cancer Res; 2018 Jan; 24(2):360-369. PubMed ID: 29118061 [No Abstract] [Full Text] [Related]
26. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304 [No Abstract] [Full Text] [Related]
28. Apoptotic regulator BCL-2 blockade as a potential therapy in classical Hodgkin Lymphoma. Gamboa-Cedeño AM; Díaz M; Cristaldo N; Otero V; Schutz N; Fantl D; Cugliari S; Zerga M; Rojas-Bilbao E; Jauk F; García Rivello H; Nuñez M; Ranuncolo SM Life Sci; 2021 Mar; 268():118979. PubMed ID: 33421528 [TBL] [Abstract][Full Text] [Related]
29. Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment. Chen X; Glytsou C; Zhou H; Narang S; Reyna DE; Lopez A; Sakellaropoulos T; Gong Y; Kloetgen A; Yap YS; Wang E; Gavathiotis E; Tsirigos A; Tibes R; Aifantis I Cancer Discov; 2019 Jul; 9(7):890-909. PubMed ID: 31048321 [TBL] [Abstract][Full Text] [Related]
30. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leonard JT; Rowley JS; Eide CA; Traer E; Hayes-Lattin B; Loriaux M; Spurgeon SE; Druker BJ; Tyner JW; Chang BH Sci Transl Med; 2016 Aug; 8(354):354ra114. PubMed ID: 27582059 [TBL] [Abstract][Full Text] [Related]
31. Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax. Leverson JD; Sampath D; Souers AJ; Rosenberg SH; Fairbrother WJ; Amiot M; Konopleva M; Letai A Cancer Discov; 2017 Dec; 7(12):1376-1393. PubMed ID: 29146569 [TBL] [Abstract][Full Text] [Related]
32. Venetoclax in the treatment of chronic lymphocytic leukemia. Korycka-Wolowiec A; Wolowiec D; Kubiak-Mlonka A; Robak T Expert Opin Drug Metab Toxicol; 2019 May; 15(5):353-366. PubMed ID: 30969139 [TBL] [Abstract][Full Text] [Related]
33. Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement. Liu L; Mo W; Chen M; Qu Y; Wang P; Liang Y; Yan X BMC Cancer; 2024 Jun; 24(1):761. PubMed ID: 38918775 [TBL] [Abstract][Full Text] [Related]